Literature DB >> 29161720

Development of OSTQOL: A Measure of Quality of Life for Patients in Opioid Substitution Treatment.

Lisa Strada1, Gabriele Helga Franke2, Bernd Schulte1, Jens Reimer1,3, Uwe Verthein1.   

Abstract

BACKGROUND: Quality of life (QOL) of patients in opioid substitution treatment (OST) is increasingly being addressed in research. However, no disease- or treatment-specific instrument is available to assess the QOL of this target population. The purpose of this project was to develop the first QOL instrument for OST patients.
METHODS: Focus groups with 60 OST patients were analyzed using thematic analysis to elicit key QOL themes as perceived by patients. Identified themes were developed into items and refined through pilot testing and cognitive debriefing. The resulting 82 items were tested in a large sample of OST patients (n = 577). Principal component analysis with varimax rotation was performed to explore a possible factor structure and reduce the number of items. Psychometric properties were assessed.
RESULTS: Factor analysis revealed 6 subscales accounting for 46.1% of the variance: Personal Development, Mental Distress, Social Contacts, Material Well-being, Opioid Substitution Treatment, and Discrimination. The 38-item instrument demonstrated good to acceptable internal consistency reliability for all subscales (Cronbach's alpha = 0.75-0.88), and good convergent and discriminant validity.
CONCLUSION: The Opioid Substitution Treatment Quality of Life scale (OSTQOL) is a multidimensional instrument with low respondent and administrator burden. A thorough validation is needed to assess its validity.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Instrument; Opioid substitution treatment; Patient-reported outcome; Quality of life; Reliability

Mesh:

Year:  2017        PMID: 29161720     DOI: 10.1159/000484239

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  8 in total

Review 1.  Opioid use disorder.

Authors:  John Strang; Nora D Volkow; Louisa Degenhardt; Matthew Hickman; Kimberly Johnson; George F Koob; Brandon D L Marshall; Mark Tyndall; Sharon L Walsh
Journal:  Nat Rev Dis Primers       Date:  2020-01-09       Impact factor: 52.329

2.  Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.

Authors:  Nicholas Lintzeris; Adrian J Dunlop; Paul S Haber; Dan I Lubman; Robert Graham; Sarah Hutchinson; Shalini Arunogiri; Victoria Hayes; Peter Hjelmström; Agneta Svedberg; Stefan Peterson; Fredrik Tiberg
Journal:  JAMA Netw Open       Date:  2021-05-03

3.  Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?

Authors:  John Marsden; Betty Tai; Robert Ali; Lian Hu; A John Rush; Nora Volkow
Journal:  Addiction       Date:  2019-01-30       Impact factor: 6.526

4.  Performance of the WHOQOL-BREF among Norwegian substance use disorder patients.

Authors:  Ashley Elizabeth Muller; Svetlana Skurtveit; Thomas Clausen
Journal:  BMC Med Res Methodol       Date:  2019-03-04       Impact factor: 4.615

5.  Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.

Authors:  John Marsden; Mike Kelleher; Eilish Gilvarry; Luke Mitcheson; Zoë Hoare; Dyfrig Hughes; Jatinder Bisla; Angela Cape; Fiona Cowden; Edward Day; Jonathan Dewhurst; Rachel Evans; Andrea Hearn; Joanna Kelly; Natalie Lowry; Martin McCusker; Caroline Murphy; Robert Murray; Tracey Myton; Sophie Quarshie; Gemma Scott; Sophie Turner; Rob Vanderwaal; April Wareham
Journal:  Trials       Date:  2022-08-19       Impact factor: 2.728

6.  Factors associated with health-related quality of life in a large national sample of patients receiving opioid substitution treatment in Germany: A cross-sectional study.

Authors:  Lisa Strada; Christiane Sybille Schmidt; Moritz Rosenkranz; Uwe Verthein; Norbert Scherbaum; Jens Reimer; Bernd Schulte
Journal:  Subst Abuse Treat Prev Policy       Date:  2019-01-03

7.  Quality of life and well-being from the perspective of patients on opioid agonist maintenance treatment: study protocol for a systematic review of qualitative research and a scoping review of measures.

Authors:  Ivan Solà; Joan Trujols; Elisa Ribalta; Saul Alcaraz; Gemma Robleda; Clara Selva Olid; José Pérez de Los Cobos
Journal:  Syst Rev       Date:  2019-12-01

8.  Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment.

Authors:  Kirsten Marchand; Julie Foreman; Scott MacDonald; Scott Harrison; Martin T Schechter; Eugenia Oviedo-Joekes
Journal:  Subst Abuse Treat Prev Policy       Date:  2020-01-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.